Wu Tsai Human Performance Alliance
Showing 11-20 of 167 Results
Baker Family Director of Stanford ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology
BioProfessor Carolyn Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars important to human health and disease. Her research group profiles changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and uses this information to develop new diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.
Dr. Bertozzi completed her undergraduate degree in Chemistry at Harvard University and her Ph.D. at UC Berkeley, focusing on the chemical synthesis of oligosaccharide analogs. During postdoctoral work at UC San Francisco, she studied the activity of endothelial oligosaccharides in promoting cell adhesion at sites of inflammation. She joined the UC Berkeley faculty in 1996. A Howard Hughes Medical Institute Investigator since 2000, she came to Stanford University in June 2015, among the first faculty to join the interdisciplinary institute ChEM-H (Chemistry, Engineering & Medicine for Human Health). She is now the Baker Family Director of Stanford ChEM-H.
Named a MacArthur Fellow in 1999, Dr. Bertozzi has received many awards for her dedication to chemistry, and to training a new generation of scientists fluent in both chemistry and biology. She has been elected to the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences; and received the Lemelson-MIT Prize, the Heinrich Wieland Prize, the ACS Award in Pure Chemistry, and the Chemistry of the Future Solvay Prize, among others.
The Bertozzi Group develops chemical tools to study the glycobiology underlying diseases such as cancer, inflammation, tuberculosis and most recently COVID-19. She is the inventor of "bioorthogonal chemistry", a class of chemical reactions compatible with living systems that enable molecular imaging and drug targeting. Her group also developed new therapeutic modalities for targeted degradation of extracellular biomolecules, such as antibody-enzyme conjugates and Lysosome Targeting Chimeras (LYTACs). As well, her group studies NGly1 deficiency, a rare genetic disease characterized by loss of the human N-glycanase.
Several of the technologies developed in the Bertozzi lab have been adapted for commercial use. Actively engaged with several biotechnology start-ups, Dr. Bertozzi cofounded Redwood Bioscience, Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, OliLux Bio, Grace Science LLC and Lycia Therapeutics. She is also a member of the Board of Directors of Lilly.
Associate Professor of Orthopaedic Surgery
Current Research and Scholarly InterestsThe long-term goal of our research is to understand the fundamental mechanisms that govern and reprogram cellular fate during development, regeneration and disease.
UPS Foundation Professor and Senior Fellow at the Woods Institute for the Environment
BioOur group studies the impact of building design, materials, and symbols on human wellbeing including stress, physical activity, creativity, sense of belonging, and pro-environmental behavior. We are exploring how buildings can include both physical and digital adaptations to improve wellbeing outcomes including new methods of bringing nature and the experience of nature into buildings. We are interested in how building management systems can be extended beyond providing energy savings, thermal comfort, and security to support and maintain a broader set of human wellbeing outcomes while preserving occupant privacy. Further, we are studying the impact of built features, including historic structures, on community wellbeing and methods of design for community wellbeing that support the equitable development of affordable and permanent supportive housing.
Our group also has a long history of expertise in the design and evaluation of sustainable, durable construction materials, their application to structures and construction, including damage-tolerant, high-performance fiber-reinforced cementitious composite materials, and bio-based fiber-reinforced polymeric composites and insulating foams that have a closed loop life-cycle.
Helen M. Blau
Donald E. and Delia B. Baxter Foundation Professor, Director, Baxter Laboratory for Stem Cell Biology and Professor, by courtesy, of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsProf. Helen Blau's research area is regenerative medicine with a focus on stem cells. Her research on nuclear reprogramming and demonstrating the plasticity of cell fate using cell fusion is well known and her laboratory has also pioneered the design of biomaterials to mimic the in vivo microenvironment and direct stem cell fate. Current findings are leading to more efficient iPS generation, cell based therapies by dedifferentiation a la newts, and discovery of novel molecules and therapies.
Charles and Elizabeth Prothro Professor of Marine Sciences, Professor of Oceans and Senior Fellow at the Woods Institute for the Environment
Current Research and Scholarly InterestsThermal physiology, open ocean predators, ecological physiology and tuna biology
Helen Bronte-Stewart, MD, MS
John E. Cahill Family Professor, Professor of Neurology and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsMy research focus is human motor control and brain pathophysiology in movement disorders. Our overall goal is to understand the role of the basal ganglia electrical activity in the pathogenesis of movement disorders. We have developed novel computerized technology to measure fine, limb and postural movement. With these we are measuring local field potentials in basal ganglia nuclei in patients with Parkinson's disease and dystonian and correlating brain signalling with motor behavior.
Marion S. Buckwalter, MD, PhD
Professor of Neurology and of Neurosurgery
Current Research and Scholarly InterestsThe goal of the Buckwalter Lab is to improve how people recover after a stroke. We use basic and clinical research to understand the cells, proteins, and genes that lead to successful recovery of function, and also how complications develop that impact quality of life after stroke. Ongoing projects are focused on understanding how inflammatory responses are regulated after a stroke and how they affect short-term brain injury and long term outcomes like dementia and depression.